NEW YORK, Aug. 27 (GenomeWeb News) - The Translational Genomics Research Institute said yesterday that it has formed a collaboration with the Institute of Genomic Medicine in Mexico to research diseases that disproportionately affect Hispanics. Their first focus will be gastric cancer, the second leading cause of malignant tumors in Mexico, according to TGen. Other diseases to be explored include diabetes.
“The sequencing of the human genome has taught us that subtle genetic variations exist within populations,” INMEGEN director Gerardo Jiménez-Sánchez said in a statement. “This collaboration will allow us to focus specifically on those nuances to better define the disease process as it pertains to the Mexican population, while at the same time, add important details to the puzzle that is the disease process as a whole.”
TGen said the arrangement with INMEGEN is its first international partnership, and marks its fifth research collaboration in its 14 months of operation.
In April the Ariz.-based organization inked separate deals with the Southwest Autism Research and Resource Center, to test and possibly treat autistics, and with the IBM Functional Genomics and Systems Biology Group, to research the computational analysis of gene expression.
In June, TGen said it was partnering with the Salt River Pima-Maricopa Indian community and the city of Phoenix, Ariz.to study the genetic basis of diabetes, and then announced it would study melanoma with the Mayo Clinic Cancer Center, Arizona State University, and the University of Arizona.